{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-104154","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.232055+00:00","generated_at":"2026-05-17T01:22:53.846113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"INmune Bio Q3 net loss $6.5M; appoints new CEO, CFO; INKmune trial meets primary endpoint","bullets":["Net loss narrowed to $6.5M from $12.1M YoY; R&D spend cut to $4.9M; cash $27.7M.","David Moss appointed President & CEO replacing Dr. RJ Tesi; Cory Ellspermann named CFO.","XPro1595 Phase 2 MINDFuL results manuscript submitted; End-of-Phase 2 meeting with FDA expected Q1 2026.","INKmune CARE-PC trial met primary endpoint and 2 of 3 secondary endpoints; trial closed to recruitment.","CORDStrom commercial pilot runs complete; MAA submission on track for mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-104154","json":"https://secwatch.observer/filing/0001213900-25-104154.json","markdown":"https://secwatch.observer/filing/0001213900-25-104154.md","text":"https://secwatch.observer/filing/0001213900-25-104154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/0001213900-25-104154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/ea0263196-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:22:53.846113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}